These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 35292153)
1. How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)? Catapano AL; Daccord M; Damato E; Humphries SE; Neely RDG; Nordestgaard BG; Pistollato M; Steinhagen-Thiessen E Atherosclerosis; 2022 May; 349():136-143. PubMed ID: 35292153 [TBL] [Abstract][Full Text] [Related]
2. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Kronenberg F; Mora S; Stroes ESG; Ference BA; Arsenault BJ; Berglund L; Dweck MR; Koschinsky ML; Lambert G; Mach F; McNeal CJ; Moriarty PM; Natarajan P; Nordestgaard BG; Parhofer KG; Virani SS; von Eckardstein A; Watts GF; Stock JK; Ray KK; Tokgözoğlu LS; Catapano AL Atherosclerosis; 2023 Jun; 374():107-120. PubMed ID: 37188555 [TBL] [Abstract][Full Text] [Related]
3. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives. Wu MF; Xu KZ; Guo YG; Yu J; Wu Y; Lin LM Cardiovasc Drugs Ther; 2019 Dec; 33(6):739-748. PubMed ID: 31655942 [TBL] [Abstract][Full Text] [Related]
4. Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresis. Klingel R; Heigl F; Schettler V; Roeseler E; Grützmacher P; Hohenstein B; Vogt A; Fassbender C; Heibges A; Julius U Atheroscler Suppl; 2019 Dec; 40():17-22. PubMed ID: 31818445 [TBL] [Abstract][Full Text] [Related]
5. Lipoprotein (a): When to Measure and How to Treat? Rhainds D; Brodeur MR; Tardif JC Curr Atheroscler Rep; 2021 Jul; 23(9):51. PubMed ID: 34235598 [TBL] [Abstract][Full Text] [Related]
6. Prevalence of lipoprotein(a) measurement in patients with or at risk of cardiovascular disease. Panza GA; Blazek O; Tortora J; Saucier S; Fernandez AB J Clin Lipidol; 2023; 17(6):748-755. PubMed ID: 37926592 [TBL] [Abstract][Full Text] [Related]
7. To test, or not to test: that is the question for the future of lipoprotein(a). Ellis KL; Chakraborty A; Moses EK; Watts GF Expert Rev Cardiovasc Ther; 2019 Apr; 17(4):241-250. PubMed ID: 30916582 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network. Catapano AL; Tokgözoğlu L; Banach M; Gazzotti M; Olmastroni E; Casula M; Ray KK; Atherosclerosis; 2023 Apr; 370():5-11. PubMed ID: 36894469 [TBL] [Abstract][Full Text] [Related]
9. Consensus and guidelines on lipoprotein(a) - seeing the forest through the trees. Kronenberg F; Mora S; Stroes ESG Curr Opin Lipidol; 2022 Dec; 33(6):342-352. PubMed ID: 36251423 [TBL] [Abstract][Full Text] [Related]
10. Lipoprotein(a) and mortality-a high risk relationship. Klingel R; Heibges A; Fassbender C Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):13-19. PubMed ID: 30838554 [TBL] [Abstract][Full Text] [Related]
15. Trends and consequences of lipoprotein(a) testing: Cross-sectional and longitudinal health insurance claims database analyses. Stürzebecher PE; Schorr JJ; Klebs SHG; Laufs U Atherosclerosis; 2023 Feb; 367():24-33. PubMed ID: 36764050 [TBL] [Abstract][Full Text] [Related]
16. Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. Virani SS; Koschinsky ML; Maher L; Mehta A; Orringer CE; Santos RD; Shapiro MD; Saseen JJ Prog Cardiovasc Dis; 2022; 73():32-40. PubMed ID: 35063437 [TBL] [Abstract][Full Text] [Related]
17. Burden of elevated lipoprotein(a) among patients with atherosclerotic cardiovascular disease: Evidence from a systematic literature review and feasibility assessment of meta-analysis. Orfanos P; Fonseca AF; Hu X; Gautam R; Montgomery G; Studer R; Kaur J; Saxena N; Kaushik N PLoS One; 2023; 18(11):e0294250. PubMed ID: 37983217 [TBL] [Abstract][Full Text] [Related]
18. Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH. Anagnostis P; Rizos CV; Skoumas I; Rallidis L; Tziomalos K; Skalidis E; Kotsis V; Doumas M; Kolovou G; Sfikas G; Garoufi A; Lambadiari V; Dima I; Kiouri E; Agapakis D; Zacharis E; Antza C; Kolovou V; Koumaras C; Bantouvakis G; Liamis G; Liberopoulos EN Endocrine; 2022 May; 76(2):324-330. PubMed ID: 35262845 [TBL] [Abstract][Full Text] [Related]
19. Lipoprotein(a) and Increased Cardiovascular Risk in Women. Costello BT; Silverman ER; Doukky R; Braun LT; Aggarwal NT; Deng Y; Li Y; Lundberg G; Williams KA; Volgman AS Clin Cardiol; 2016 Feb; 39(2):96-102. PubMed ID: 26880352 [TBL] [Abstract][Full Text] [Related]
20. In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members. Zawacki AW; Dodge A; Woo KM; Ralphe JC; Peterson AL J Clin Lipidol; 2018; 12(6):1445-1451. PubMed ID: 30150142 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]